CDK2 targeting program (Monte Rosa Therapeutics)

N/A

Report date: 2025/01/26 19:36:48

NME

Base Information

Drug NameCDK2 targeting program (Monte Rosa Therapeutics)

Drug Alias NameCyclin-dependent kinase-2 modulator molecular glue degrader (Monte Rosa Therapeutics)Cyclin-dependent kinase-2 modulator QuEEN technology (Monte Rosa Therapeutics)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionCyclin-dependent kinase 2 modulatorsCereblon modulators

TargetsCereblonCyclin-dependent kinase 2

Therapy Area/IndicationsOvarian NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMonte Rosa Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesMonte Rosa Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A